ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

MOR MorphoSys AG

18.18
0.00 (0.00%)
24 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
MorphoSys AG MOR NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 18.18 15:30:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
18.20 17.95 18.26 18.18 18.18
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
20/6/202401:47BWMorphoSys and Novartis Sign Delisting Agreement and Intend..
10/6/202410:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/6/202415:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/6/202409:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/6/202415:06EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
04/6/202409:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/5/202409:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/5/202409:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/5/202409:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/5/202409:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/5/202413:19EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
23/5/202409:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/5/202408:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/5/202409:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/5/202409:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/5/202415:43EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
16/5/202409:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/5/202409:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/5/202409:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/4/202415:01BWMorphoSys AG Reports First Quarter 2024 Financial Results
11/4/202407:39BWMorphoSys’ Management Board and Supervisory Board Recommend..
13/3/202415:02BWMorphoSys AG Reports Fourth Quarter and Full Year 2023..
06/2/202405:14IHMARKETNEWSBoeing Faces Strike Threat, Palantir Up 18% After Recording..
10/12/202318:31BWMorphoSys’ Pelabresib Improves All Four Hallmarks of..
20/11/202316:19DJNMorphoSys Trial for Blood-Cancer Treatment Reaches Primary..
20/11/202315:30BWMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis..
15/11/202315:01BWMorphoSys AG Reports First Nine Months and Third Quarter..
09/8/202315:01BWMorphoSys AG Reports Second Quarter and First Half 2023..

Su Consulta Reciente

Delayed Upgrade Clock